ONEHUNDRED NINE PATIENTS with limited-stage unresonable non-small-cell lung cancer were treated with Adriamycin-cisplatin-based combination chemotherapy and thoracic irradiation. Of this number, 73 received chemotherapy (one course) prior to irradiation and 377 (27/73) had tumor regression following chemotherapy alone Sixty-eight percent of patients (73/107) experienced tumor regression following combined chemotherapy and irradiation. Ags more than 65 years, a maligant ipsilateral pleural effusion and no response to chenotherapy alone were all strong negative prognosticactors. Three-year survivals were as follows all 109 patients, 14.0% 89 patients without malignant pleural effusion, 17.0% 71 patients with neither a malignant pleural effusion nor malignant ipsilateral supraclavicular adenopathy, 23.1%.
a Division of Medical Oncology, Department of Oncology. May, Clinic, Rochester, Minnesota.
b Division of Therapeutic Radiology, Department of Oncology, Mayo Clinic, Rochester, Minnesota. c Department of Medical Research Statistics and Epidemiology, Mayo Clinic, Rochester, Minnesota.